In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, <em>Acinetobacter baumannii</em>, and <em>Pseudomonas aeruginosa</em> Strains at a Tertiary Hospital in Korea

• Main Authors: Le Phuong Nguyen (Author), Chul Soon Park (Author), Naina Adren Pinto (Author), Hyunsook Lee (Author), Hyun Soo Seo (Author), Thao Nguyen Vu (Author), Hung Mai (Author), An H. T. Pham (Author), Eris Jang (Author), Young Lag Cho (Author), Karrie Goglin (Author), Kevin Nguyen (Author), Richard White (Author), Roshan D'Souza (Author), Derrick E. Fouts (Author), Dongeun Yong (Author)
• Format: Book
• Published: MDPI AG, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The siderophore-antibiotic conjugate LCB10-0200 (a.k.a. GT-1) has been developed to combat multidrug-resistant Gram-negative bacteria. In this study, the in vitro activity of LCB10-0200 and LCB10-0200/avibactam (AVI) has been investigated against carbapenem-resistant <i>Escherichia coli</i&...